Brief: Galmed Announces Top-Line Results In Oncology MoA Studies A 3-Drug Combination Of Aramchol, Stivarga® And Metformin Significantly Enhanced Gi Tumor Cells, Killing In-Vivo And In-Vitro
17/11/2025 13:39
Galmed Pharmaceuticals Ltd GLMD.O: GALMED ANNOUNCES TOP-LINE RESULTS IN ONCOLOGY MOA STUDIES: A 3-DRUG COMBINATION OF ARAMCHOL, STIVARGA® AND METFORMIN SIGNIFICANTLY ENHANCED GI TUMOR CELLS, KILLING IN-VIVO AND IN-VITRO Source text: ID:nPn7wrlSha Further company coverage: GLMD.O